F. Vincenti, C. P. Larsen, J. Alberu, B. Bresnahan, V. D. Garcia, J. Kothari, P. Lang, E. Mancilla Urrea, P. Massari, G. Mondragon-Ramirez, R. Reyes-Acevedo, K. Rice, L. Rostaing, S. Steinberg, J. Xing, M. Agarwal, M. B. Harler and B. Charpentier Three-Year Outcomes from BENEFIT, a Randomized, Active-Controlled, Parallel-Group Study in Adult Kidney Transplant Recipients American Journal of Transplantation 12
Article first published online: 12 OCT 2011 | DOI: 10.1111/j.1600-6143.2011.03785.x
Three-year results from the BENEFIT study confirm the durability of the renal function benefits of belatacept over time compared to cyclosporine, balancing the early risks (acute rejection, posttransplant lymphoproliferative disorder) associated with belatacept.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field